Evidence map›Paper›PMID 39506136›Full record

ReviewBritish journal of cancer2025

Cardiotoxicity following thoracic radiotherapy for lung cancer.

Gerard M Walls, Carmen Bergom, Joshua D Mitchell, Stacey L Rentschler, Geoffrey D Hugo, Pamela P Samson, Clifford G Robinson

Erratum issuedAbstract readReview
In one paragraph

Review in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Cardiac substructure dosimetry in thoracic radiotherapy: moving beyond mean heart dose and toward precision cardiac risk mitigation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Review
  14. Review
  15. Review
  16. Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gerard M WallsDepartment of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA. g.walls@qub.ac.uk.ORCID http://orcid.org/0000-0003-0845-9732
Carmen BergomDepartment of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA.ORCID https://orcid.org/0000-0002-0886-5055
Joshua D MitchellCardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA.ORCID https://orcid.org/0000-0001-7371-5742
Stacey L RentschlerDepartment of Developmental Biology, Washington University in St Louis, St. Louis, MO, USA.ORCID https://orcid.org/0000-0002-1744-1238
Geoffrey D HugoDepartment of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA.
Pamela P SamsonDepartment of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA.ORCID https://orcid.org/0000-0003-2448-2123
Clifford G RobinsonDepartment of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA.ORCID https://orcid.org/0000-0002-1399-9904

Funding

Mechanistic Basis of Cardiac Irradiation as a Therapy for Ventricular TachycardiaR01HL163274 · NHLBI · WASHINGTON UNIVERSITY · PI RENTSCHLER, STACEY LYNN, SCHWARZ, JULIE KRISTINA · 2022 to 2025
$3.1M
Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failureR01HL165792 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BAUR, JOSEPH A. · 2022 to 2025
$2.7M
Genetic Modifiers of Radiation Therapy-Induced CardiotoxicityR01HL147884 · NHLBI · WASHINGTON UNIVERSITY · PI BERGOM, CARMEN · 2019 to 2023
$2.3M
NHLBI NIH HHS R01 HL147884NHLBI NIH HHS R01 HL163274NHLBI NIH HHS R01 HL165792
6 · The paper itself

Abstract

Radiotherapy is the standard of care treatment for unresectable NSCLC, combined with concurrent chemotherapy and adjuvant immunotherapy. Despite technological advances in radiotherapy planning and delivery, the risk of damage to surrounding thoracic tissues remains high. Cardiac problems, including arrhythmia, heart failure and ischaemic events, occur in 20% of patients with lung cancer who undergo radiotherapy. As survival rates improve incrementally for this cohort, minimising the cardiovascular morbidity of RT is increasingly important. Problematically, the reporting of cardiac endpoints has been poor in thoracic radiotherapy clinical trials, and retrospective studies have been limited by the lack of standardisation of nomenclature and endpoints. How baseline cardiovascular profile and cardiac substructure radiation dose distribution impact the risk of cardiotoxicity is incompletely understood. As Thoracic Oncology departments seek to expand the indications for radiotherapy, and as the patient cohort becomes older and more comorbid, there is a pressing need for cardiotoxicity to be comprehensively characterised with sophisticated oncology, physics and cardio-oncology evaluations. This review synthesises the evidence base for cardiotoxicity in conventional radiotherapy, focusing on lung cancer, including current data, unmet clinical needs, and future scientific directions.

Indexed as

Carcinoma, Non-Small-Cell LungCardiotoxicityLung NeoplasmsRadiotherapyHumans

Identifiers

PMID39506136
PMCPMC11833127

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.